Objectives Lorlatinib is a potent 3rd generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with ALK positive advanced non-small cell lung cancer (NSCLC) previously treated with one or more ALK tyrosine kinase inhibitors (TKIs). The present study assessed the cost-effectiveness of Lorlatinib versus pemetrexed with platinum combination of carboplatin or cisplatin (platinum based ChT) in Greece.Conclusions The present analysis suggests that Lorlatinib may be considered a cost-effective option over platinum based ChT in Greece, for the treatment of patients with ALK positive advanced NSCLC who have progressed after one or more ALK TKIs, while covering a significant unmet medical need. READ ARTICLE
Value in Health DOI:10.1016/j.jval.2020.08.244
Authors: G. Gourzoulidis, O. Zisimopoulou, N. Boubouchairopoulou, C. Michailidi, C. Almond, C. Tzanetakos, G. Kourlaba,